Literature DB >> 6692374

Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

T H Corbett, B J Roberts, W R Leopold, J C Peckham, L J Wilkoff, D P Griswold, F M Schabel.   

Abstract

Following implant of cotton thread-carrying 3-methyl-cholanthrene into the pancreas tissue of 90 C57BL/6 and 60 BALB/c mice, 13 developed ductal adenocarcinomas. Two of these tumors, both of C57BL/6 origin (Panc 02 and 03), were established in serial s.c. transplant. Panc 02 was treated with 37 different anticancer drugs representing all of the chemical and functional classes of clinically useful anticancer agents including alkylating agents, antimetabolites, agents that bind to or cause scission of DNA, and others that inhibit mitosis or inhibit protein synthesis. When drug treatment was started within 3 to 4 days after tumor implant, Panc 02 showed only limited response to treatment with two nitrosoureas, [N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N- nitrosourea, monohydrochloride and N-(2-chloroethyl)-N'-(2,6-dioxo-3-piperdinyl)-N-nitrosourea)], and N-phosphonacetyl-L-aspartate. Drug response of Panc 03 was determined only with Adriamycin, 5-fluorouracil, cyclophosphamide, cis-(SP-4-2)-diamminedichloroplatinum, or N,N'-bis(2-chloroethyl)-N-nitrosourea. When drug treatment was started 3 days after tumor implant, high cure rates were obtained with Adriamycin treatment, and limited therapeutic responses were seen to treatment with cis-diamminedichloroplatinum or cyclophosphamide. A comparison of the biological characteristics and drug responsiveness of Panc 02 and Panc 03 with those of a number of other transplantable tumors of mice is reported.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692374

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  163 in total

1.  Activity of batracylin (NSC-320846) against solid tumors of mice.

Authors:  P Mucci-LoRusso; L Polin; M C Bissery; F Valeriote; J Plowman; G D Luk; T H Corbett
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

2.  Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours.

Authors:  Johanne Seguin; Céline Nicolazzi; Nathalie Mignet; Daniel Scherman; Guy G Chabot
Journal:  Tumour Biol       Date:  2012-06-07

3.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

Review 4.  Transgenic models of pancreatic cancer.

Authors:  Andrew M Lowy
Journal:  Int J Gastrointest Cancer       Date:  2003

5.  Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations.

Authors:  Qiaofei Liu; Ronghua Zhang; Xiang Zhang; Jingkai Liu; Huanwen Wu; Yuan Li; Ming Cui; Tong Li; Huixin Song; Junyi Gao; Yalu Zhang; Sen Yang; Quan Liao
Journal:  Cancer Immunol Immunother       Date:  2021-01-17       Impact factor: 6.968

6.  Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.

Authors:  Dirk Spitzer; Peter O Simon; Hiroyuki Kashiwagi; Jinbin Xu; Chenbo Zeng; Suwanna Vangveravong; Dong Zhou; Katherine Chang; Jonathan E McDunn; John R Hornick; Peter Goedegebuure; Richard S Hotchkiss; Robert H Mach; William G Hawkins
Journal:  Cancer Res       Date:  2011-11-07       Impact factor: 12.701

7.  Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat.

Authors:  Gail L Matters; Timothy K Cooper; Christopher O McGovern; Evan L Gilius; Jiangang Liao; Brian M Barth; Mark Kester; Jill P Smith
Journal:  Dig Dis Sci       Date:  2014-05-11       Impact factor: 3.199

8.  Cancer causes increased mortality and is associated with altered apoptosis in murine sepsis.

Authors:  Amy C Fox; Charles M Robertson; Brian Belt; Andrew T Clark; Katherine C Chang; Ann M Leathersich; Jessica A Dominguez; Erin E Perrone; W Michael Dunne; Richard S Hotchkiss; Timothy G Buchman; David C Linehan; Craig M Coopersmith
Journal:  Crit Care Med       Date:  2010-03       Impact factor: 7.598

9.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Authors:  Jonathan B Mitchem; Donal J Brennan; Brett L Knolhoff; Brian A Belt; Yu Zhu; Dominic E Sanford; Larisa Belaygorod; Danielle Carpenter; Lynne Collins; David Piwnica-Worms; Stephen Hewitt; Girish Mallya Udupi; William M Gallagher; Craig Wegner; Brian L West; Andrea Wang-Gillam; Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

10.  Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer.

Authors:  B K Chang; J A Gregory
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.